Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Protagenic Therapeutics, Inc.\new PTIX

13 fiscal years on record · USD · FY2025 reported · SEC filings only

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income 1.4
0.5M1.0M-2.0M-4.0M
20132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
ROE
FY2023 · ROE -94.5%
-50%-100%
201320192025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -2.8
-2M-3M
201320192025

Total assetsUSD 3.7M
EquityUSD 2.6M
CashUSD 1.5M
Current ratio1.50×

Equity funds 72% of total assets.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PTIX, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.00.00.00.00.00.0◌◌◌0.00.00.0◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌
EBITDA $B−0.0−0.0−0.0−0.0◌−0.0−0.0−0.0−0.0−0.0−0.0−0.0◌
Income tax $B◌◌◌◌◌◌◌◌◌0.00.00.00.0
Net income $B0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0◌−0.0−0.0◌◌◌◌◌◌−0.0−0.0−0.0
EPS, diluted $0.59−0.67−1.15−0.82−0.31−0.25−0.17−0.25−0.22−0.43−0.150.00◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %——−94.5−42.2————−122.3———◌
Shares out B0.000.010.000.000.020.010.010.010.010.010.010.40◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 49 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. Seven checks were skipped: EPS is not tagged before 2014.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsMarch 31
SEC categorysmaller reporting company
Data on record since2012

Share this section

Download image